Contact Info

About Me

Dr. Xiaoyang Xu comes to NJIT from MIT, where he was an NIH postdoctoral fellow advised by Institute Professor Robert Langer and co-mentored by Professor Omid Farokhzad (Harvard Medical School). He completed his Ph.D. in Material Chemistry at Northwestern University under the supervision of Prof. Chad Mirkin. His research focus is the development of novel biomaterials and nanotechnologies for a variety of medical applications including diagnosis, bioimaging, drug delivery, and regenerative medicine. He looks at both fundamental and applied questions in the cross-disciplinary fields of biomaterials and medicine in order to develop novel therapeutic methods for the treatment of cancer, obesity, and cardiovascular disease. His research has been published in high-impact journals such as the Proceedings of the National Academy of Sciences of the United States of America, the Journal of the American Chemical Society, Angewandte Chemie International Edition, ACS Nano, Nano Letters, Small and Advanced Materials.

Website

Website

Research Interest

Utilizing chemistry, materials science and engineering techniques, we explore the interface of biomaterials and medicine and address fundamental questions in the two cross-disciplinary fields.

One specific goal lies in developing multifunctional biomaterials for medical applications including therapeutic delivery and regenerative medicine. For example, we investigate the synergistic effects of combinatorial drug delivery for cancer treatment through the creation of nanocarrier plaforms which can simultaneously deliver therapeutics and small interfering RNA (siRNA).

In parallel, we are interested in developing synthetic biomaterials and processing techniques to fabricate hydrogels and scaffolds for use in drug delivery and tissue engineering. In particular we focus on biomaterials engineering to understand structure-function relationships and investigate the effects of biomaterials characteristics on therapeutics release, and cellular/tissue interactions.